LabCorp and its Specialty Testing Group, a fully integrated portfolio of specialty and esoteric testing laboratories.
This test covers all coding nucleotides of 20 genes: A2ML1, BRAF, CBL, HRAS, KRAS, LZTR1, MAP2K1, MAP2K2, MRAS, NF1, NRAS, PTPN11, RAF1, RIT1, RRAS, RASA2, SHOC2, SOS1, SOS2, and SPRED1, plus at least two and typically 10 flanking intronic nucleotides upstream and downstream of each coding exon, covering the conserved donor and acceptor splice sites, as well as typically 10 flanking nucleotides in the 5' and 3' UTR.
Test orders must include an attestation that the provider has the patient's informed consent for genetic testing. See sample physician office consent form: Consent for Genetic Testing. For family testing, please call customer service at 866-647-0735 before submitting specimens for family testing (ie, known mutations).
16 - 24 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
For more information, please view the literature below.
10 mL, or 30 mL if ordering multiple tests
Yellow-top (ACD) tube or lavender-top (EDTA) tube
Maintain specimen at room temperature.
Frozen or hemolyzed specimen; container broken or leaking; container not labeled or label not legible
Confirm a clinical diagnosis of Noonan syndrome and identify presymptomatic family members, guiding prophylactic measures. See Prenatal Noonan Syndrome (451890) for fetal testing.
Confirm a clinical diagnosis of Noonan syndrome and identify presymptomatic family members, guiding prophylactic measures.
Confirm a clinical diagnosis of Noonan syndrome and identify presymptomatic family members, guiding prophylactic measures..
This analysis does not rule out: germline mosaicism, the presence of large chromosomal aberrations, including deletions, insertions, and rearrangements, mutations in regions or genes not included in this test, and possible inter/intragenic interactions between sequence variants. False-positive results or false-negative results may occur for reasons that include genetic variants, blood transfusions, bone marrow transplantation, mislabeled specimens, or erroneous representation of family relationships.
Mutation analysis is performed using the AgilentSure Select XT® enrichment method and the Illumina® next-generation sequencing platform. Regions of interest include all exons and splice junctions for each gene and limited regions for the following: APOB (556bp of exon 26) and MED12 ( c.3020A>G). Sequencing reads are aligned with the hg19 build of the human genome reference sequence. Analytical sensitivity is based on the depth of coverage across the regions of interest and is provided separately for each gene. Greater than 98% of target bases are synonymous variants not previously recorded at greater than or equal to 20x coverage. Sanger sequencing isused to confirm mutation identity and analyze regions with low coverage. Variants are reported using numbering and nomenclature recommended by the Human Genome Variation Society (HGVS). Variants known to be benign and synonymous variants not previously recorded in our internal variant data bases are not reported.
Noonan syndrome and Noonan-like syndromes tend to be associated predominantly with different genes or different variants within the same genes. Clinical overlap of the various syndromes is explained by the fact that all of these genes code for components of the same intracellular signaling pathway, namely the RAS/MAPK signaling cascade.
Genetic testing for Noonan syndrome and related disorders may:
• Establish or confirm a clinical diagnosis of Noonan syndrome, Leopard syndrome, Costello syndrome, or cardiofaciocutaneous syndrome.
• Identify previously undiagnosed parents, siblings, and other relatives of patients with Noonan syndrome or Leopard syndrome.
• Facilitate appropriate genetic counseling for family members.
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|
|451441||GeneSeq: Noonan Syndrome||451331||Specimen Type:||31208-2|
|451441||GeneSeq: Noonan Syndrome||451403||Results:||48003-8|
|451441||GeneSeq: Noonan Syndrome||451438||Key Findings||53037-8|
|451441||GeneSeq: Noonan Syndrome||451439||Additional Information||49549-9|
|451441||GeneSeq: Noonan Syndrome||451694||Gene Information||51968-6|
|451441||GeneSeq: Noonan Syndrome||451772||Tech Spec Results||51958-7|
|451441||GeneSeq: Noonan Syndrome||451773||Seq Variants Detected||69548-6|
|451441||GeneSeq: Noonan Syndrome||451409||Disclaimer||N/A|
|451441||GeneSeq: Noonan Syndrome||451774||Director Review:||48672-0|
|451441||GeneSeq: Noonan Syndrome||451775||51969-4|
© 2020 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
The LOINC® codes are copyright © 1994-2020, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf